Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for TN-401 in Arrhythmogenic Right Ventricular Cardiomyopathy. The expected timing is based on the latest available company guidance and may change.
RIDGE-1 trial. 10/2023- Received IND Clearance. 8/8/24- Received CTA clearance in UK. 7/30/25- Received positive safety review from DSMB. 11/13/25- Cohort 1 data in Q4 2025. 12/11/25:- Interim RIDGE-1 Cohort 1 Ph1b data show good safety, PKP2 expression, reduced arrhythmia burden. 03/11/26:- DSMB endorsed RIDGE-1 dosing. One-year Cohort 1 and initial Cohort 2 data H1 2026; more Cohort 2 data H2 2026. 04/27/26:- RIDGE-1 interim safety/biopsy/efficacy data to present at ASGCT May 15, 2026. Webcast planned. 05/06/26:- ASGCT late-breaker May 15, 2026 will present RIDGE-1 Cohort 1 one-year and initial Cohort 2 data; DSMB endorsed expansion. 05/15/26:- RIDGE-1 interim Ph1b/2 data showed reduced PVCs; well tolerated. EMA PRIME granted; future readouts TBA. 08/05/26:- RIDGE-1 interim data positive; additional data and regulatory update expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.